<DOC>
	<DOCNO>NCT00006397</DOCNO>
	<brief_summary>The purpose study see safe effective give multi-drug treatment indinavir ( IDV ) plus ritonavir ( RTV ) plus enteric-coated didanosine ( ddI ) plus stavudine ( d4T ) differences response men woman .</brief_summary>
	<brief_title>Differences Between Women Men Taking Combination Indinavir , Ritonavir , Enteric-Coated Didanosine , Stavudine Who Previously Took Anti-HIV Drugs</brief_title>
	<detailed_description>Patients enrol balanced number base gender stratify viral load ( less equal 10,000 , 10,000 100,000 , 100,000 copies/ml ) . Prior therapy , peer-based patient education intervention present . Patients receive combination IDV , RTV , enteric-coated ddI , d4T . Responses multi-agent antiretroviral drug regimen explore base sex difference . A pharmacokinetic sub-study , balance half patient male half female , perform IDV RTV 20 25 patient . About 20 female examine study-drug effect gonadotropic hormone level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load ( amount HIV blood ) great 500 copies/ml . Have receive antiHIV treatment previously NNRTI plus NRTI combination NRTIs great 8 week , currently treatment , treatment 12 week less . Failed keep viral load low previous antiHIV treatment . Are least 18 year age . Agree use effective barrier method birth control . Exclusion Criteria Patients eligible study : Have use protease inhibitor 14 day . Have use ddI d4T 30 day . Are pregnant breastfeeding . Have opportunistic ( AIDSrelated ) infection require treatment time enrollment . Have , appear , peripheral neuropathy ( painful condition affect nervous system ) time screen . Are risk , , pancreatitis ( disease pancreas ) . Have difficulty absorb medication . Have cancer , Kaposi 's sarcoma , may require systemic treatment . Have medical condition treatment may cause rise viral load . Have condition previous treatment would interfere study . Are unable take drug mouth . Are receive receive recently follow drug : terfenadine , astemizole , cisapride , triazolam , midazolam , ergot alkaloid , amiodarone , bepridil , flecainide , propafenone , quinidine , pimozide , rifampin , intravenous ( IV ) pentamidine . Are receive vincristine , thalidomide , foscarnet , cisplatin medication may cause nerve damage . Have receive experimental drug within 30 day prior treatment . Are receive treatment testosterone , anabolic steroid , growth hormone , megestrol acetate , except certain hormonal problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Sex Factors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>